1 active not recruiting, 1 completed, 1 recruiting, 1 terminated. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 1, Completed 1, Recruiting 1, Terminated 1, Unknown 1 |
Follow Adjuvant Chemotherapy: new trials by email Literature Review of Adjuvant Chemotherapy trials Research Report on Adjuvant Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy Tislelizumab, Fruquintinib - Minimal Residual Disease, Adjuvant Chemotherapy | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2025-09-18 | 2026-08-12 |
| Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer Capecitabine - ctDNA, Colorectal Cancer (CRC) | Phase 2 | Recruiting | Fudan University | 80 | 2024-11-01 | 2026-05-01 |
| A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan S-1 - Resected Pancreatic Cancer, Pancreatic Cancer | Phase 2 | Terminated | TTY Biopharm | 36 | 2019-07-11 | 2021-12-06 |
| IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy, Intensified Follow-up Schedule - Colorectal Cancer, Circulating Tumor DNA | Phase 2 | Unknown | Karen-Lise Garm Spindler | 64 | 2018-10-01 | 2022-02-25 |
| Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma Gemcitabine plus cisplatin, Capecitabine - Cholangiocarcinoma, Biliary Tract Cancer | Phase 2 | Completed | Asan Medical Center | 101 | 2017-05-15 | 2022-12-06 |
Colorectal Neoplasms (3) · Biliary Tract Neoplasms (1) · Cholangiocarcinoma (1) · Neoplasm, Residual (1) · Pancreatic Neoplasms (1)
Digestive System Diseases (5) · Digestive System Neoplasms (5) · Neoplasms (5) · Neoplasms by Site (5) · Colonic Diseases (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Rectal Diseases (3) · Adenocarcinoma (1) · Biliary Tract Diseases (1) · Carcinoma (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1)
Capecitabine (2) · Cisplatin (1) · Gemcitabine (1) · HMPL-013 (1) · S 1 (combination) (1) · tislelizumab (1)
Asan Medical Center (1) · Fudan University (1) · Karen-Lise Garm Spindler (1) · M.D. Anderson Cancer Center (1) · TTY Biopharm (1)
China (1) · Denmark (1) · South Korea (1) · Taiwan (1) · United States (1)
Arvind Dasari, MD (1) · Baek-Yeol Ryoo, MD (1)